Mainz Biomed B.V. (MYNZ) News
Filter MYNZ News Items
MYNZ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MYNZ News Highlights
- MYNZ's 30 day story count now stands at 4.
- Over the past 14 days, the trend for MYNZ's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about MYNZ are DEC, ALT and CRC.
Latest MYNZ News From Around the Web
Below are the latest news stories about MAINZ BIOMED NV that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for EmployeesHermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and Crimmitschau, in Q1 2024BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the second phase of its colorectal cance |
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in PolandBERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation. The first attended conferenc |
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal CancerObesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in obese individuals. Therefore, this is a highly lucrative segment for pharmaceutical companies. Yet, the big pharma giant, Pfizer Inc (NYSE: PFE) abandoned its obesity drug that failed during the phase 2 trial due to exhibited side-effects. But a clinical-stage company, Altimmune Inc (NASDAQ: ALT), an |
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA BiomarkersGroundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82%Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same DesignColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA Biomarkers in Pivotal FDA PMA Clinical Trial (ReconAAsense); Trial is On Track to Commence Enrollment in Mid-2024 BERKELEY, Calif. and MAINZ, Germany, Dec. 05, 2023 (GLOBE NEWSWIRE) -- |
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via WebcastBERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presentation at the 35th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive Officer, Guido Baechler and Bill Caragol, Chief Financial Officer, will be available to view live and post event via webcast by registering at the follo |
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare ConferenceBERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer, and Bill Caragol, Chief Financial Officer, will present at the 35th Annual Piper Sandler Healthcare Conference taking place on the 28-30 November, 2023 in New York, NY, USA. The conference will bring together key indust |
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80% BERKELEY, Calif. and MAINZ, Germany, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced toda |
Mainz Biomed Announces Closing of $5.0 million Registered Direct OfferingBERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced registered direct offering with several institutional investors to purchase $5.0 million of its ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary sha |
Mainz Biomed Announces Pricing of $5.0 million Registered Direct OfferingBERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a securities purchase agreement with several institutional investors to purchase $5.0 million of its ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares in a r |
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening TestCollaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processingBERKELEY, Calif. and MAINZ, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE) to se |